



**HAL**  
open science

# Pharmacological characterization of the receptors involved in the b-adrenoceptor-mediated stimulation of the L-type Ca<sup>2+</sup> current in frog ventricular myocytes

V Arvydas Skeberdis, Jonas Jurevičius, Rodolphe Fischmeister

## ► To cite this version:

V Arvydas Skeberdis, Jonas Jurevičius, Rodolphe Fischmeister. Pharmacological characterization of the receptors involved in the b-adrenoceptor-mediated stimulation of the L-type Ca<sup>2+</sup> current in frog ventricular myocytes. *British Journal of Pharmacology*, 1997, 121 (7), pp.1277-1286. 10.1038/sj.bjp.0701268 . hal-03617394

**HAL Id: hal-03617394**

**https:**

**//hal-universite-paris-saclay.archives-ouvertes.fr/hal-03617394**

Submitted on 23 Mar 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Pharmacological characterization of the receptors involved in the $\beta$ -adrenoceptor-mediated stimulation of the L-type $\text{Ca}^{2+}$ current in frog ventricular myocytes

V. Arvydas Skeberdis, Jonas Jurevičius & <sup>1</sup>Rodolphe Fischmeister

Laboratoire de Cardiologie Cellulaire et Moléculaire, INSERM U-446, Université de Paris-Sud, Faculté de Pharmacie, F-92296 Châtenay-Malabry, France

**1** The whole-cell patch-clamp was used for studying the effects of various  $\beta_1$ - and  $\beta_2$ -adrenoceptor agonists and antagonists on the L-type Ca current ( $I_{\text{Ca}}$ ) in frog ventricular myocytes.

**2** Dose-response curves for the effects of isoprenaline (non selective  $\beta$ -agonist), salbutamol ( $\beta_2$ -agonist), dobutamine ( $\beta_1$ -agonist) on  $I_{\text{Ca}}$  were obtained in the absence and presence of various concentrations of ICI 118551 ( $\beta_2$ -antagonist), metoprolol ( $\beta_1$ -antagonist) and xamoterol (partial  $\beta_1$ -agonist) to derive  $\text{EC}_{50}$  (i.e. the concentration of  $\beta$ -agonist at which the response was 50% of the maximum) and  $\text{E}_{\text{max}}$  (the maximal response) values by use of a Michaelis equation. Schild regression analysis was performed to examine whether the antagonists were competitive and to determine the equilibrium dissociation constant ( $K_{\text{B}}$ ) for the antagonist-receptor complex.

**3** Isoprenaline increased  $I_{\text{Ca}}$  with an  $\text{EC}_{50}$  of 20.0 nM and an  $\text{E}_{\text{max}}$  of 597%. ICI 118551 and metoprolol competitively antagonized the effect of isoprenaline with a  $K_{\text{B}}$  of 3.80 nM and 207 nM, respectively.

**4** Salbutamol increased  $I_{\text{Ca}}$  with an  $\text{EC}_{50}$  of 290 nM and an  $\text{E}_{\text{max}}$  of 512%. ICI 118551 and metoprolol competitively antagonized the effect of salbutamol with a  $K_{\text{B}}$  of 1.77 nM and 456 nM, respectively.

**5** Dobutamine increased  $I_{\text{Ca}}$  with an  $\text{EC}_{50}$  of 2.40  $\mu\text{M}$  and an  $\text{E}_{\text{max}}$  of 265%. ICI 118551 and metoprolol competitively antagonized the effect of dobutamine with a  $K_{\text{B}}$  of 2.84 nM and 609 nM, respectively.

**6** Xamoterol had no stimulating effect on  $I_{\text{Ca}}$ . However, xamoterol competitively antagonized the stimulating effects of isoprenaline, salbutamol and dobutamine on  $I_{\text{Ca}}$  with a  $K_{\text{B}}$  of 58–64 nM.

**7** We conclude that a single population of receptors is involved in the  $\beta$ -adrenoceptor-mediated regulation of  $I_{\text{Ca}}$  in frog ventricular myocytes. The pharmacological pattern of the response of  $I_{\text{Ca}}$  to the different  $\beta$ -adrenoceptor agonists and antagonists tested suggests that these receptors are of the  $\beta_2$ -subtype.

**Keywords:**  $\text{Ca}^{2+}$  current; frog heart;  $\beta_1$ -adrenoceptor agonists and antagonists;  $\beta_2$ -adrenoceptor agonists and antagonists; dobutamine; metoprolol; ICI 118551; xamoterol; salbutamol; isoprenaline

## Introduction

$\beta_1$ - and  $\beta_2$ -adrenoceptors coexist in the heart of various animal species, including man. Both receptors are positively coupled to the adenylyl cyclase system and participate in the mediation of the positive chronotropic and inotropic effects of catecholamines (for reviews, see Stiles *et al.*, 1984; Brodde, 1991). However, the relative amount of each receptor subtype as well as the post-receptor cellular signalling pathways may differ significantly depending on the cardiac tissue, the animal species, the pathophysiological state, the age or the developmental stage (for reviews, see Stiles *et al.*, 1984; Brodde, 1991; 1993; Hieble & Ruffolo, 1991 and references therein). Competitive radioligand binding studies performed in membranes from homogenized hearts have shown that only 20–30% of the total  $\beta$ -adrenoceptors are of the  $\beta_2$ -subtype in adult mammalian ventricular tissue (Stiles *et al.*, 1984; Brodde, 1991; Hieble & Ruffolo, 1991). This number is even further reduced when purified cardiac myocytes rather than homogenized tissues are used (Lau *et al.*, 1980; Buxton & Brunton, 1985; Freissmuth *et al.*, 1986; Kuznetsov *et al.*, 1995; Cerbai *et al.*, 1995). Yet, selective activation of  $\beta_2$ -adrenoceptors produces a large increase in the amplitude of contraction in intact mammalian cardiac muscle (Cerbai *et al.*, 1990; Lemoine & Kaumann, 1991; Brodde, 1991) as well as in isolated ventricular myocytes (del Monte *et al.*, 1993; Xiao & Lakatta, 1993; Xiao *et al.*, 1994; 1995; Altschuld *et al.*, 1995; Kuznetsov *et al.*, 1995).

Moreover, selective  $\beta_2$ -adrenoceptor activation was found to produce a stimulation of the L-type  $\text{Ca}^{2+}$  channel current ( $I_{\text{Ca}}$ ) in guinea-pig atrial myocytes (Iijima & Taira, 1989), and in rat (Xiao & Lakatta, 1993; Xiao *et al.*, 1994; 1995; Cerbai *et al.*, 1995), guinea-pig (Wang & Pelzer, 1995; but see Iijima & Taira, 1989) and dog ventricular myocytes (Altschuld *et al.*, 1995). When compared to the effect produced by non-selective  $\beta$ -adrenoceptor agonists such as isoprenaline, the  $\beta_2$ -response may represent 25–100% of the isoprenaline response (Xiao & Lakatta, 1993; Altschuld *et al.*, 1995). This suggests that the two receptors may differ in their signalling cascade (Lemoine & Kaumann, 1991; Borea *et al.*, 1992; Xiao & Lakatta, 1993; Xiao *et al.*, 1994; 1995; Kuznetsov *et al.*, 1995; but see Skeberdis *et al.*, 1996) or in the post-receptor amplification mechanisms (Waelbroeck *et al.*, 1983; Bristow *et al.*, 1989; Green *et al.*, 1992; Levy *et al.*, 1993).

Unlike in the mammalian heart, the  $\beta$ -adrenoceptor population in the frog heart is composed of a majority ( $\approx 80\%$ ) of  $\beta_2$ -receptors (Stene-Larsen & Helle, 1978; Hancock *et al.*, 1979; Port *et al.*, 1992; Hieble & Ruffolo, 1991). Thus, one may question the functional role of  $\beta_1$ -adrenoceptors in this preparation and their contribution to the sympathetic control of heart function. For this reason, we have undertaken a pharmacological characterization of the  $\beta$ -adrenoceptor regulation of  $I_{\text{Ca}}$  in whole-cell patch-clamped single frog ventricular myocytes. Most particularly, we quantified the contribution of  $\beta_1$ - and  $\beta_2$ -receptor subtypes in the stimulating effect of the non-selective  $\beta$ -adrenoceptor agonist isoprenaline on  $I_{\text{Ca}}$ , by use of, respectively, metoprolol and ICI 118551 as selective antagonists of  $\beta_1$ - and  $\beta_2$ -receptors (Bilski *et al.*, 1983; Bylund

<sup>1</sup> Author for correspondence at: INSERM U-446, Faculté de Pharmacie, F-92296 Châtenay-Malabry Cedex, France.

*et al.*, 1994). We also investigated the effect of selective  $\beta_1$ - and  $\beta_2$ -receptor activation on  $I_{Ca}$  by use of, respectively, dobutamine and salbutamol as selective agonists of these receptors (Bylund *et al.*, 1994). Finally, we examined the effect of xamoterol, a partial  $\beta_1$ -adrenoceptor agonist (Brodde, 1991; Bylund *et al.*, 1994) on  $I_{Ca}$ . All our results converge towards the participation of a single population of receptors in the  $\beta$ -adrenoceptor-mediated regulation of  $I_{Ca}$  in frog ventricular myocytes. These receptors essentially resemble the pharmacologically defined  $\beta_2$ -adrenoceptors of mammalian preparations.

A preliminary account of this work was presented at the 41<sup>st</sup> Annual Meeting of the Biophysical Society, New Orleans, U.S.A., March 1997 (Skeberdis *et al.*, 1997).

## Methods

The investigation conforms with the European Community guiding principles in the care and use of animals (86/609/CEE, CE Off J n°L358, 18 December 1986) and the French decree n°87/748 of October 19, 1987 (J Off République Française, 20 October 1987, pp. 12245–12248). Authorizations to perform animal experiments according to this decree were obtained from the French Ministère de l'Agriculture et de la Forêt (n°04226, April 12, 1991).

### Cell dissociation

Ventricular cells were enzymatically dispersed from frog (*Rana esculenta*) heart, by a combination of collagenase and trypsin as described by Fischmeister & Hartzell (1986). Frogs were decapitated and double pithed. The isolated cells were stored in storage Ringer solution, and kept at 4°C until use (2–48 h following dissociation).

### Electrophysiological experiments

The whole-cell configuration of the patch-clamp technique was used to record the high-threshold calcium current ( $I_{Ca}$ ) on  $Ca^{2+}$ -tolerant frog ventricular myocytes. In the routine protocols the cells were depolarized every 8 s from a holding potential of  $-80$  mV to 0 mV for 200 ms. Application of tetrodotoxin ( $0.3 \mu\text{M}$ ) was used to eliminate fast sodium currents.  $K^+$  currents were blocked by replacing all  $K^+$  ions with intracellular and extracellular  $Cs^+$ . Voltage-clamp protocols were generated by a challenger/09-VM programmable function generator (Kinetic Software, Atlanta, GA). The cells were voltage-clamped by use of a patch-clamp amplifier (model RK-400; Bio-Logic, Claix, France). Currents were sampled at a frequency of 10 kHz by a 16-bit analogue-to-digital converter (PCL816, Advantech France, Levallois Perret, France) connected to a PC compatible 486/66 micro computer.

Control or drug-containing solutions were applied to the exterior of the cell by placing the cell at the opening of  $300 \mu\text{m}$  inner diameter capillary tubings flowing at a rate of  $\approx 50 \mu\text{l min}^{-1}$  (Fischmeister & Hartzell, 1986). Changes in extracellular solutions were automatically achieved by a rapid solution changer (RSC100, Bio-Logic, Claix, France). All experiments were done at room temperature ( $19$ – $25^\circ\text{C}$ ), and the temperature did not change by more than  $1^\circ\text{C}$  in a given experiment.

### Data analysis

The maximal amplitude of whole-cell  $I_{Ca}$  was measured as previously described (Fischmeister & Hartzell, 1986; Argibay *et al.*, 1988). Currents were not compensated for capacitive and leak currents. On-line analysis of the recordings was made possible by programming a PC-compatible 486/66 microcomputer in Assembling language (Borland, U.S.A.) to determine, for each membrane depolarization, peak and steady-state current values (Fischmeister & Hartzell, 1986).

Cumulative dose-response curves were obtained by testing 4 or 5 successively increasing concentrations of a  $\beta$ -adrenoceptor agonist on  $I_{Ca}$  in the presence and absence of a  $\beta$ -adrenoceptor antagonist. For each concentration of agonist, a percentage increase in  $I_{Ca}$  amplitude with respect to its 'basal' level in the absence of agonist was calculated: (% increase in  $I_{Ca}$ ) =  $100[(I_{Ca} \text{ with agonist}) - (\text{basal } I_{Ca})] / (\text{basal } I_{Ca})$ . For each individual experiment, the results obtained were fit to the Michaelis equation: (% increase in  $I_{Ca}$ ) =  $E_{\text{max}}[\text{agonist}] / ([\text{agonist}] + EC_{50})$ . The  $E_{\text{max}}$  values from several similar experiments are given in the text and/or figure legends as means  $\pm$  s.e. mean. The results of a given experiment were then normalized by dividing each individual '% increase in  $I_{Ca}$ ' value by  $E_{\text{max}}$ . The normalized values from several similar experiments were then averaged and are represented as percentage of maximal response by means (symbols)  $\pm$  s.e. mean (vertical lines) in the corresponding dose-response curves. These average values were fit to the Michaelis equation again to derive an average  $EC_{50}$  value, i.e. the concentration of agonist required to produce 50% of the maximal increase in  $I_{Ca}$ . In the absence of antagonist,  $EC_{50}$  was  $EC_{50}^0$ ; in the presence of a concentration [X] of antagonist,  $EC_{50}$  was  $EC_{50}^X$ . Antagonist potency was determined by Schild regression (Kenakin, 1993). The logarithms of dose-ratios minus 1, i.e.  $\log(EC_{50}^X/EC_{50}^0 - 1)$ , were plotted as a function of the logarithms of molar concentrations of the antagonist, i.e.  $\log[X]$ , and fit to a straight line by use of a least-means squares regression analysis. The Schild coefficient was determined from the slope of the line. The Schild coefficient was considered to be equal to unity if the slope was within a 95% confidence limit range of 0.9–1.2 (Kenakin, 1993). If this was the case, the equilibrium dissociation constant ( $K_B$ ) for the antagonist-receptor complex was calculated for each dose-response curve as:  $\log(K_B) = \log[X] - \log(EC_{50}^X/EC_{50}^0 - 1)$ .  $K_B$  values given in the text are the means  $\pm$  s.e. mean of 3 or 4 values, depending on the number of antagonist concentrations tested.

## Materials

For the preparation of frog ventricular myocytes, the ionic composition of  $Ca^{2+}$ -free Ringer solution was (mM): NaCl 88.4, KCl 2.5,  $\text{NaHCO}_3$  23.8,  $\text{NaH}_2\text{PO}_4$  0.6,  $\text{MgCl}_2$  1.8, creatine 5, D-glucose 10 and 1 mg  $\text{ml}^{-1}$  fatty acid-free bovine serum albumin, 50 i u  $\text{ml}^{-1}$  penicillin, 50  $\mu\text{g ml}^{-1}$  streptomycin; pH 7.4 maintained with 95%  $\text{O}_2$ , 5%  $\text{CO}_2$ . Storage Ringer solution was  $Ca^{2+}$ -free Ringer solution to which was added 0.9 mM  $\text{CaCl}_2$  and 10  $\mu\text{l ml}^{-1}$  non-essential and essential amino acid and vitamin solution (MEM 100 $\times$ ). Dissociation medium was composed of  $Ca^{2+}$ -free Ringer solution to which was added 0.2 mg  $\text{ml}^{-1}$  trypsin type XIII (Sigma, St. Louis, U.S.A.), 0.14 mg  $\text{ml}^{-1}$  collagenase (Yakult, Tokyo, Japan), and 10  $\mu\text{l ml}^{-1}$  M199 medium (Sigma).

For electrophysiology, the control external solution contained (in mM): NaCl 107, HEPES 10, CsCl 20,  $\text{NaHCO}_3$  4,  $\text{NaH}_2\text{PO}_4$  0.8,  $\text{MgCl}_2$  1.8,  $\text{CaCl}_2$  1.8, D-glucose 5, sodium pyruvate 5 and tetrodotoxin  $3 \times 10^{-4}$ , pH 7.4 adjusted with NaOH. Patch electrodes (0.6–2.0 M $\Omega$ ) were filled with control internal solution which contained (mM): CsCl 119.8, EGTA (acid form) 5,  $\text{MgCl}_2$  4, creatine phosphate disodium salt 5,  $\text{Na}_2\text{ATP}$  3.1,  $\text{Na}_2\text{GTP}$  0.42,  $\text{CaCl}_2$  (pCa 8.5) 0.062 and HEPES 10; pH 7.1 adjusted with CsOH.

Tetrodotoxin was from Latoxan (Rosans, France). The  $\beta$ -adrenoceptor agonists and antagonists used were: isoprenaline (Sigma), salbutamol (Sigma), xamoterol (Tocris Cookson, Bristol, U.K.), dobutamine (Tocris Cookson), ICI 118551 (erythro-1-(7-methylindan-4-yloxy)-3-isopropylamino-butan-2-ol; Tocris Cookson), and metoprolol (ICN Biomedicals Inc., Aurora, Ohio, U.S.A.). All other drugs were from Sigma. Salbutamol was solubilized in ethanol and all other  $\beta$ -adrenoceptor compounds were dissolved in distilled water. Each day, fresh 1–10 mM stock solutions were prepared and stored

at 4°C. Immediately before being applied to the cell, the drug was dissolved at the desired final concentration in control external solution, i.e. only fresh solutions were tested. In the case of salbutamol, an appropriate amount of ethanol was added to each solution so that the same ethanol concentration as that present in the solution containing the highest concentration of the drug was present in all solutions tested.


## Results

### Regulation of $I_{Ca}$ by the non-selective $\beta$ -adrenoceptor agonist isoprenaline

Figure 1a shows a typical experiment with isoprenaline as a non-selective  $\beta$ -adrenoceptor agonist to stimulate  $I_{Ca}$  in a frog ventricular myocyte.  $I_{Ca}$  was measured every 8 s by depolarizing the cell over a period of 200 ms from a holding potential of  $-80$  mV. As shown earlier (Fischmeister & Hartzell, 1986; Hartzell *et al.*, 1991), isoprenaline produced a dose-dependent increase in  $I_{Ca}$ . A cumulative dose-response curve for the effect of isoprenaline on  $I_{Ca}$  is presented in Figure 1c (■). The data are normalized to the maximal stimulation of  $I_{Ca}$  ( $E_{max}$ ) which was derived from the fit of the experimental points to the Michaelis equation (see Methods). Thus, isoprenaline increased  $I_{Ca}$  with an  $EC_{50}$  value of 20.0 nM and  $E_{max}$  was  $597 \pm 105\%$  ( $n=9$ ).

To examine the participation of  $\beta_2$ -adrenoceptors in the stimulating effect of isoprenaline on  $I_{Ca}$ , the same type of experiment was repeated in the presence of different concentrations of ICI 118551, a selective  $\beta_2$ -adrenoceptor antagonist. As shown in the typical experiment of Figure 1b, ICI 118551 (used at 100 nM in this experiment) was applied first to the myocyte which was then exposed to increasing concentrations of isoprenaline. ICI 118551 alone had no effect on  $I_{Ca}$  at any of the concentrations used (1 nM to 1  $\mu$ M, data not shown). However, in the presence of the drug, larger concentrations of isoprenaline were required to stimulate  $I_{Ca}$  (Figure 1b, c). The mean data points in Figure 1c show the response of  $I_{Ca}$  to isoprenaline in the presence of 1 nM, 10 nM, 100 nM and 1  $\mu$ M ICI 118551. The dose-response curve for the response of  $I_{Ca}$  to isoprenaline was progressively shifted to higher concentrations of the agonist when increasing concentrations of the  $\beta_2$ -antagonist were used. A Schild regression analysis (see Methods) of the five curves presented in Figure 1c allowed us to determine a Schild coefficient close to 1 (1.08) and a  $K_B$  of  $3.80 \pm 0.90$  nM ( $n=4$ ) for the inhibitory effect of ICI 118551 on the response of  $I_{Ca}$  to isoprenaline. This suggests that, in the range of concentrations used (1 nM to 100  $\mu$ M), isoprenaline activates  $I_{Ca}$  through a single population of receptors which bind ICI 118551 in the low nanomolar range of concentrations.

We then examined the participation of  $\beta_1$ -adrenoceptors in the stimulating effect of isoprenaline on  $I_{Ca}$ . Thus, the same type of experiment as above was repeated in the presence of different concentrations of metoprolol, a selective  $\beta_1$ -adrenoceptor antagonist. As shown in the typical experiment of Figure 2a, a frog myocyte was exposed at first to metoprolol (used at 10  $\mu$ M in this experiment) and subsequently to increasing concentrations of isoprenaline in the presence of metoprolol. Metoprolol alone had no effect on  $I_{Ca}$  at any of the concentrations used (10 nM to 10  $\mu$ M, data not shown). However, in the presence of the drug, larger concentrations of isoprenaline were required to stimulate  $I_{Ca}$  (e.g. compare Figure 1a and 2a). The mean data points in Figure 2b show the response of  $I_{Ca}$  to isoprenaline alone (■, taken from Figure 1c) or in the presence of 10 nM, 100 nM, 1  $\mu$ M and 10  $\mu$ M metoprolol. The dose-response curve for the response of  $I_{Ca}$  to isoprenaline was progressively shifted to higher concentrations of the agonist when increasing concentrations of the  $\beta_1$ -antagonist were used. A competition curve analysis of the five curves of Figure 2b allowed us to determine a Schild coefficient




**Figure 1** Effect of isoprenaline and ICI 118551 on  $I_{Ca}$  in frog ventricular cells. (a) A frog ventricular myocyte was initially superfused with control external solution and internally dialysed with control intracellular solution. Each symbol represents the maximal peak amplitude of  $I_{Ca}$  obtained by depolarizing the cell every 8 s to 0 mV over a period of 200 ms from a holding potential of  $-80$  mV. During the periods indicated by the horizontal lines, the cell was successively exposed to five increasing concentrations of isoprenaline (0.001, 0.01, 0.1, 1 and 10  $\mu$ M). (b) The same experiment as in (a) but in the presence of 100 nM ICI 118551. After application of the  $\beta_2$ -antagonist, the cell was successively exposed to five increasing concentrations of isoprenaline (0.01, 0.1, 1, 10 and 30  $\mu$ M). The current traces shown in the insets of (a) and (b) were recorded at the times indicated by the corresponding letters on the main graphs. (c) Concentration-response curve for the stimulating effect of isoprenaline on  $I_{Ca}$ . The effect of increasing concentrations of isoprenaline on  $I_{Ca}$  were obtained in several experiments performed in the absence of ICI 118551 as in (a) (control) or in the presence of 1 nM, 10 nM, 100 nM (as in (b)) or 1  $\mu$ M ICI 118551. The points show the mean and vertical lines s.e.mean of the number of cells indicated. The continuous line was derived from a non-linear least-mean-squares regression of the means to the Michaelis equation (see Methods). The concentration of isoprenaline ( $EC_{50}$ ) required for half-maximal stimulation of  $I_{Ca}$  and the maximal effect of isoprenaline ( $E_{max}$ ) were derived from this analysis:  $EC_{50}$  and  $E_{max}$  values were: 20.0 nM and 597% in control; 25.8 nM and 1237% with 1 nM ICI 118551; 120 nM and 435% with 10 nM ICI 118551; 470 nM and 322% with 100 nM ICI 118551; 3.70  $\mu$ M and 744% with 1  $\mu$ M ICI 118551. The data were normalized to  $E_{max}$  and are presented as percentage of the maximal response to isoprenaline.

close to 1 (1.06) and a  $K_B$  of  $207 \pm 51.9$  nM ( $n=3$ ) for the inhibitory effect of metoprolol on the response of  $I_{Ca}$  to isoprenaline. This suggests again that isoprenaline activates  $I_{Ca}$  through a single population of receptors. These receptors are sensitive to metoprolol in the high nanomolar range of concentrations.


### Regulation of $I_{Ca}$ by the selective $\beta_2$ -adrenoceptor agonist salbutamol

We have shown earlier that zinterol and salbutamol, two selective  $\beta_2$ -adrenoceptor agonists, stimulate  $I_{Ca}$  in frog ventricular myocytes and produce a similar maximal effect as isoprenaline (Skeberdis *et al.*, 1996). We have now characterized in more detail the response of  $I_{Ca}$  to salbutamol. As shown in the typical experiment of Figure 3a, salbutamol produced a dose-dependent increase in  $I_{Ca}$ . A cumulative dose-response curve for the effect of salbutamol on  $I_{Ca}$  is presented in Figure 3c (■). Salbutamol increased  $I_{Ca}$  with an  $EC_{50}$  value of 290 nM and  $E_{max}$  was  $512 \pm 69\%$  ( $n=6$ ). To examine the participation of  $\beta_2$ - and  $\beta_1$ -adrenoceptors in the stimulating effect of salbutamol on  $I_{Ca}$ , the same type of experiment was repeated in the presence of different concentrations of ICI 118551 (Figure 3b




**Figure 2** Effect of isoprenaline and metoprolol on  $I_{Ca}$ . (a) A frog ventricular myocyte was initially superfused with control external solution in the presence of 10  $\mu$ M metoprolol. During the periods indicated, the cell was successively exposed to four increasing concentrations of isoprenaline (0.1, 1, 10 and 100  $\mu$ M). The current traces shown in the inset were recorded at the times indicated by the corresponding letters on the main graph. (b) Concentration-response curve for the stimulating effect of isoprenaline on  $I_{Ca}$ . The effects of increasing concentrations of isoprenaline on  $I_{Ca}$  were obtained in several experiments performed in the absence of metoprolol (Control, same data as in Figure 1c) or in the presence of 100 nM, 1  $\mu$ M or 10  $\mu$ M metoprolol (as in (a)). The points show the mean and vertical lines s.e.mean of the number of cells indicated.  $EC_{50}$  and  $E_{max}$  values were: 20.0 nM and 597% in control; 34.9 nM and 287% with 100 nM metoprolol; 85.1 nM and 240% with 1  $\mu$ M metoprolol; 1.13  $\mu$ M and 715% with 10  $\mu$ M metoprolol. The data were normalized to  $E_{max}$  and are presented as percentage of the maximal response to isoprenaline.

and c) or metoprolol (Figure 4). As shown in the typical experiments of Figure 3b and Figure 4a, ICI 118551 (used at 10 nM in Figure 3b) and metoprolol (used at 0.1  $\mu$ M in Figure 4a) reduced the sensitivity of  $I_{Ca}$  to salbutamol, since larger concentrations of the drug were required to stimulate  $I_{Ca}$ . The mean data points in Figure 3c show the response of  $I_{Ca}$  to salbutamol in the presence of 1 nM, 10 nM and 100 nM ICI



**Figure 3** Effect of salbutamol and ICI 118551 on  $I_{Ca}$ . (a) A frog ventricular myocyte was initially superfused with control external solution. During the periods indicated, the cell was successively exposed to four increasing concentrations of salbutamol (0.01, 0.1, 1 and 10  $\mu$ M). (b) The same experiment as in (a) but in the presence of 10 nM ICI 118551. After application of the  $\beta_2$ -antagonist, the cell was successively exposed to four increasing concentrations of salbutamol (0.1, 1, 10 and 100  $\mu$ M). The current traces shown in the insets of (a) and (b) were recorded at the times indicated by the corresponding letters on the main graphs. (c) Concentration-response curve for the stimulating effect of salbutamol on  $I_{Ca}$ . The effect of increasing concentrations of salbutamol on  $I_{Ca}$  were obtained in several experiments performed in the absence of ICI 118551 as in (a) (Control) or in the presence of 1 nM, 10 nM (as in (b)) or 100 nM ICI 118551. The points show the mean and vertical lines s.e.mean of the number of cells indicated.  $EC_{50}$  and  $E_{max}$  values for the effect of salbutamol on  $I_{Ca}$  were: 290 nM and 512% in control; 0.51  $\mu$ M and 531% with 1 nM ICI 118551; 2.06  $\mu$ M and 837% with 10 nM ICI 118551; 13.0  $\mu$ M and 559% with 100 nM ICI 118551. The data were normalized to  $E_{max}$  and are presented as percentage of the maximal response to salbutamol.




**Figure 4** Effect of salbutamol and metoprolol on  $I_{Ca}$ . (a) A frog ventricular myocyte was initially superfused with control external solution in the presence of 100 nM metoprolol. During the periods indicated, the cell was successively exposed to four increasing concentrations of salbutamol (0.01, 0.1, 1 and 10  $\mu\text{M}$ ). The current traces shown in the inset were recorded at the times indicated by the corresponding letters on the main graph. (b) Concentration-response curve for the stimulating effect of salbutamol on  $I_{Ca}$ . The effect of increasing concentrations of salbutamol on  $I_{Ca}$  were obtained in several experiments performed in the absence of metoprolol (Control, same data as in Figure 3c) or in the presence of 0.1  $\mu\text{M}$  (as in (a)), 1  $\mu\text{M}$  or 10  $\mu\text{M}$  metoprolol. The points show the mean and vertical lines s.e.mean of the number of cells indicated.  $EC_{50}$  and  $E_{max}$  values were: 290 nM and 512% in control; 367 nM and 631% with 0.1  $\mu\text{M}$  metoprolol; 800 nM and 802% with 1  $\mu\text{M}$  metoprolol; 7.13  $\mu\text{M}$  and 532% with 10  $\mu\text{M}$  metoprolol. The data were normalized to  $E_{max}$  and are presented as percentage of the maximal response to salbutamol.

118551. The mean data points in Figure 4b show the response of  $I_{Ca}$  to salbutamol alone (■, taken from Figure 3c) or in the presence of 100 nM, 1  $\mu\text{M}$  and 10  $\mu\text{M}$  metoprolol. It appears that the dose-response curve for the response of  $I_{Ca}$  to salbutamol was progressively shifted to higher concentrations of the  $\beta_2$ -agonist when increasing concentrations of ICI 118551 (Figure 3c) or metoprolol (Figure 4b) were used. A Schild regression analysis (see Methods) of the curves in Figures 3c and 4b allowed us to determine Schild coefficients close to 1 (1.12 in Figure 3c, 1.02 in Figure 4b) and  $K_B$  values of  $1.77 \pm 0.28$  nM ( $n=3$ ) for the inhibitory effect of ICI 118551 and  $456 \pm 57.8$  nM ( $n=3$ ) for the inhibitory effect of metoprolol on the response of  $I_{Ca}$  to salbutamol. This suggests that, in the range of concentrations used (10 nM to 100  $\mu\text{M}$ ), salbutamol activates  $I_{Ca}$  through a single population of receptors which bind ICI 118551 in the low nanomolar range of concentrations and metoprolol in the high nanomolar range of concentrations.

#### Regulation of $I_{Ca}$ by the selective $\beta_1$ -adrenoceptor agonist dobutamine

The same strategy was applied to examine the effect of a selective  $\beta_1$ -adrenoceptor agonist, dobutamine, on  $I_{Ca}$  in frog ventricular myocytes. As shown in the experiment of Figure


5a, dobutamine produced a dose-dependent increase in  $I_{Ca}$ . A cumulative dose-response curve for the effect of dobutamine on  $I_{Ca}$  is presented in Figure 5c (■). Dobutamine increased  $I_{Ca}$  with an  $EC_{50}$  value of 2.4  $\mu\text{M}$  and  $E_{max}$  was  $265 \pm 47\%$  ( $n=7$ ). However, we found that increasing the concentration of dobutamine above 100  $\mu\text{M}$  produced severe inhibitory effects on  $I_{Ca}$  and a complete block of the current appeared at a concentration of 1 mM. Thus, in the following, only the ef-




**Figure 5** Effect of dobutamine and ICI 118551 on  $I_{Ca}$ . (a) A frog ventricular myocyte was initially superfused with control external solution. During the periods indicated, the cell was successively exposed to five increasing concentrations of dobutamine (0.1, 1, 10, 100 and 1000  $\mu\text{M}$ ). Note the dramatic inhibitory effect on  $I_{Ca}$  of the highest concentration of dobutamine. (b) The same experiment as in (a) but in the presence of 1 nM ICI 118551. After application of the  $\beta_2$ -antagonist, the cell was successively exposed to four increasing concentrations of dobutamine (0.1, 1, 10 and 100  $\mu\text{M}$ ). The current traces shown in the insets of (a) and (b) were recorded at the times indicated by the corresponding letters on the main graphs. (c) Concentration-response curve for the stimulating effect of dobutamine on  $I_{Ca}$ . The effect of increasing concentrations of dobutamine on  $I_{Ca}$  were obtained in several experiments performed in the absence of ICI 118551 as in (a) (Control) or in the presence of 1 nM (as in (b)), 3 nM or 10 nM ICI 118551. The points show the mean and vertical lines s.e.mean of the number of cells indicated.  $EC_{50}$  and  $E_{max}$  values for the effect of salbutamol on  $I_{Ca}$  were: 2.40  $\mu\text{M}$  and 265% in control; 3.28  $\mu\text{M}$  and 318% with 1 nM ICI 118551; 4.57  $\mu\text{M}$  and 203% with 3 nM ICI 118551; 12.2  $\mu\text{M}$  and 108% with 10 nM ICI 118551. The data were normalized to  $E_{max}$  and are presented as percentage of the maximal response to dobutamine.

fects of lower concentrations of dobutamine ( $\leq 100 \mu\text{M}$ ) were investigated. To examine the participation of  $\beta_2$ - and  $\beta_1$ -adrenoceptors in the stimulating effect of dobutamine on  $I_{\text{Ca}}$ , the same type of experiment was repeated in the presence of different concentrations of ICI 118551 (Figure 5b and c) or metoprolol (Figure 6). As shown in the typical experiments of Figure 5b and Figure 6a, ICI 118551 (used at 1 nM in Figure 5b) and metoprolol (used at  $0.1 \mu\text{M}$  in Figure 6a) reduced the sensitivity of  $I_{\text{Ca}}$  to dobutamine, since larger concentrations of the drug were required to stimulate  $I_{\text{Ca}}$ . The mean data points in Figure 5c show the response of  $I_{\text{Ca}}$  to dobutamine in the presence of 1 nM, 3 nM and 10 nM ICI 118551. The mean data points in Figure 6b show the response of  $I_{\text{Ca}}$  to dobutamine alone (■, taken from Figure 5c) or in the presence of 100 nM,  $1 \mu\text{M}$  and  $10 \mu\text{M}$  metoprolol. It appears that the dose-response curve for the response of  $I_{\text{Ca}}$  to dobutamine was progressively shifted to higher concentrations of the  $\beta_1$ -agonist when increasing concentrations of ICI 118551 (Figure 5c) or metoprolol (Figure 6b) were used. A Schild regression analysis (see Methods) of the curves in Figures 5c and 6b allowed us to determine Schild coefficients close to 1 (0.98 in Figure 5c, 1.11 in Figure 6b) and  $K_B$  values of  $2.84 \pm 0.26 \text{ nM}$  ( $n=3$ ) for the inhibitory effect of ICI 118551 and


$609 \pm 84.1 \text{ nM}$  ( $n=3$ ) for the inhibitory effect of metoprolol on the response of  $I_{\text{Ca}}$  to dobutamine. This suggests that, in the range of concentrations used (10 nM to  $100 \mu\text{M}$ ), dobutamine activates  $I_{\text{Ca}}$  through a single population of receptors which bind ICI 118551 in the low nanomolar range of concentrations and metoprolol in the high nanomolar range of concentrations.



**Figure 6** Effect of dobutamine and metoprolol on  $I_{\text{Ca}}$ . (a) A frog ventricular myocyte was initially superfused with control external solution in the presence of  $0.1 \mu\text{M}$  metoprolol. During the periods indicated, the cell was successively exposed to four increasing concentrations of dobutamine (0.1, 1, 10 and  $100 \mu\text{M}$ ). The current traces shown in the inset were recorded at the times indicated by the corresponding letters on the main graph. (b) Concentration-response curve for the stimulating effect of dobutamine on  $I_{\text{Ca}}$ . The effect of increasing concentrations of dobutamine on  $I_{\text{Ca}}$  were obtained in several experiments performed in the absence of metoprolol (Control, same data as in Figure 5c) or in the presence of 100 nM (as in (a)),  $1 \mu\text{M}$  or  $10 \mu\text{M}$  metoprolol. The points show the mean and vertical lines s.e.mean of the number of cells indicated.  $\text{EC}_{50}$  and  $\text{E}_{\text{max}}$  values were:  $2.40 \mu\text{M}$  and 265% in control;  $2.93 \mu\text{M}$  and 260% with 100 nM metoprolol;  $6.54 \mu\text{M}$  and 91% with  $1 \mu\text{M}$  metoprolol;  $33.7 \mu\text{M}$  and 754% with  $10 \mu\text{M}$  metoprolol. The data were normalized to  $\text{E}_{\text{max}}$  and are presented as percentage of the maximal response to dobutamine.




**Figure 7** Effect of xamoterol and isoprenaline on  $I_{\text{Ca}}$ . (a) A frog ventricular myocyte was initially superfused with control external solution. During the periods indicated, the cell was successively exposed to seven increasing concentrations of xamoterol (0.001, 0.01, 0.1, 1, 10, 100 and  $1000 \mu\text{M}$ ). (b) A frog ventricular myocyte was initially superfused with control external solution. During the periods indicated, the cell was successively exposed  $10 \mu\text{M}$  xamoterol and, then, to four increasing concentrations of isoprenaline (0.1, 1, 10 and  $100 \mu\text{M}$ ). The current traces shown in the inset of (b) were recorded at the times indicated by the corresponding letters on the main graphs. (c) Concentration-response curve for the stimulating effect of isoprenaline on  $I_{\text{Ca}}$ . The effect of increasing concentrations of isoprenaline on  $I_{\text{Ca}}$  were obtained in several experiments performed in the absence of xamoterol (Control, same data as in Figure 1c) or in the presence of  $0.1 \mu\text{M}$ ,  $1 \mu\text{M}$  or  $10 \mu\text{M}$  xamoterol (as in (b)). The points show the mean and vertical lines s.e.mean of the number of cells indicated.  $\text{EC}_{50}$  and  $\text{E}_{\text{max}}$  values were: 20.0 nM and 597% in control;  $60.0 \text{ nM}$  and 1098% with  $0.1 \mu\text{M}$  xamoterol;  $240 \text{ nM}$  and 730% with  $1 \mu\text{M}$  xamoterol;  $5.51 \mu\text{M}$  and 905% with  $10 \mu\text{M}$  xamoterol. The data were normalized to  $\text{E}_{\text{max}}$  and are presented as percentage of the maximal response to isoprenaline.



**Figure 8** Effect of dobutamine and xamoterol on  $I_{Ca}$ . (a) A frog ventricular myocyte was initially superfused with control external solution in the presence of 100 nM xamoterol. During the periods indicated, the cell was successively exposed to four increasing concentrations of dobutamine (0.1, 1, 10 and 100  $\mu\text{M}$ ). The current traces shown in the inset were recorded at the times indicated by the corresponding letters on the main graph. (b) Concentration-response curve for the stimulating effect of dobutamine on  $I_{Ca}$ . The effect of increasing concentrations of dobutamine on  $I_{Ca}$  were obtained in several experiments performed in the absence of metoprolol (Control, same data as in Figure 5c) or in the presence of 0.1  $\mu\text{M}$  (as in (a)) or 0.3  $\mu\text{M}$  xamoterol. The points show the mean and vertical lines s.e.mean of the number of cells indicated.  $EC_{50}$  and  $E_{max}$  values were: 2.40  $\mu\text{M}$  and 265% in control; 5.52  $\mu\text{M}$  and 191% with 0.1  $\mu\text{M}$  xamoterol; 21.2  $\mu\text{M}$  and 211% with 0.3  $\mu\text{M}$  xamoterol. The data were normalized to  $E_{max}$  and are presented as percentage of the maximal response to dobutamine.

### Regulation of $I_{Ca}$ by the $\beta_1$ -adrenoceptor partial agonist xamoterol

We also examined the effects of a  $\beta_1$ -adrenoceptor partial agonist, xamoterol, on  $I_{Ca}$  in frog ventricular myocytes. Surprisingly, xamoterol (from 1 nM to 1 mM), unlike dobutamine (Figure 5), did not produce any stimulating effect on  $I_{Ca}$  (Figure 7a). On the contrary, xamoterol antagonized the stimulating effect of the three other  $\beta$ -adrenoceptor agonists tested. Indeed, the individual experiments in Figures 7b, 8a and 9a show that the presence of xamoterol (10  $\mu\text{M}$  in Figure 7b, 0.1  $\mu\text{M}$  in Figure 8a, 0.1  $\mu\text{M}$  in Figure 9a) reduced the sensitivity of  $I_{Ca}$  to isoprenaline (compare Figures 7b and 1a), dobutamine (compare Figures 8a and 5a) and salbutamol (compare Figures 9a and 3a). The mean data points in Figure 7c show the response of  $I_{Ca}$  to isoprenaline alone (■, taken from Figure 1c) or in the presence of 100 nM, 1  $\mu\text{M}$  and 10  $\mu\text{M}$  xamoterol. The mean data points in Figure 8b show the response of  $I_{Ca}$  to dobutamine alone (■, taken from Figure 5c) or in the presence of 100 nM and 300 nM xamoterol. The mean



**Figure 9** Effect of salbutamol and xamoterol on  $I_{Ca}$ . (a) A frog ventricular myocyte was initially superfused with control external solution in the presence of 100 nM xamoterol. During the periods indicated, the cell was successively exposed to four increasing concentrations of salbutamol (0.1, 1, 10 and 100  $\mu\text{M}$ ). The current traces shown in the inset were recorded at the times indicated by the corresponding letters on the main graph. (b) Concentration-response curve for the stimulating effect of salbutamol on  $I_{Ca}$ . The effect of increasing concentrations of salbutamol on  $I_{Ca}$  were obtained in several experiments performed in the absence of metoprolol (Control, same data as in Figure 3c) or in the presence of 0.1  $\mu\text{M}$  (as in (a)), 1  $\mu\text{M}$  or 10  $\mu\text{M}$  xamoterol. The points show the mean and vertical lines s.e.mean of the number of cells indicated.  $EC_{50}$  and  $E_{max}$  values were: 290 nM and 512% in control; 0.80  $\mu\text{M}$  and 697% with 0.1  $\mu\text{M}$  xamoterol; 3.91 and 542% with 1  $\mu\text{M}$  xamoterol; 51.8 and 360% with 10  $\mu\text{M}$  xamoterol. The data were normalized to  $E_{max}$  and are presented as percentage of the maximal response to salbutamol.

data points in Figure 9b show the response of  $I_{Ca}$  to salbutamol alone (■, taken from Figure 3c) or in the presence of 100 nM, 1  $\mu\text{M}$  and 10  $\mu\text{M}$  xamoterol. In all cases, the dose-response curves for the response of  $I_{Ca}$  to a  $\beta$ -adrenoceptor agonist were progressively shifted to higher concentrations of the agonist when increasing concentrations of xamoterol were used. A Schild regression analysis (see Methods) of the curves in Figures 7c and 9b allowed us to determine Schild coefficients of, respectively, 0.92 and 0.99, and  $K_B$  values of  $59.1 \pm 16.4$  ( $n=3$ ) and  $64.4 \pm 7.84$  nM ( $n=3$ ), for the inhibitory effect of xamoterol on the response of  $I_{Ca}$  to isoprenaline (Figure 7c) and salbutamol (Figure 9b). Since dobutamine produced deleterious effects on  $I_{Ca}$  at concentrations  $> 100$   $\mu\text{M}$ , we were unable to obtain sufficient data to perform a satisfactory Schild regression analysis with dobutamine in the presence of high concentrations of xamoterol (Figure 8b). However, if we assume that there is competitive interaction between dobutamine and xamoterol (i.e. a Schild coefficient of 1), then the dose-response curves of Figure 8b lead to a  $K_B$  value of  $57.7 \pm 13.6$  nM ( $n=2$ ) for the inhibitory effect of xamoterol on the response of  $I_{Ca}$  to dobutamine. Since this value is very



similar to the  $K_B$  values determined from the inhibitory effect of xamoterol on the response of  $I_{Ca}$  to isoprenaline (Figure 7) and salbutamol (Figure 9), our data suggest that xamoterol binds to a single population of  $\beta$ -adrenoceptors with an affinity of  $\approx 60$  nM. Binding of xamoterol resulted in an antagonistic effect on the  $\beta$ -adrenoceptor regulation of  $I_{Ca}$ .

## Discussion

In the present study, we examined the effect of isoprenaline and several selective  $\beta_1$ - and  $\beta_2$ -adrenoceptor agonists and antagonists on the L-type  $Ca^{2+}$  current ( $I_{Ca}$ ) in frog ventricular myocytes. With the exception of xamoterol, which is a partial  $\beta_1$ -agonist, all the agonists used (isoprenaline (non-selective), salbutamol ( $\beta_2$ -selective), dobutamine ( $\beta_1$ -selective)) produced a dose-dependent stimulation of  $I_{Ca}$ . In a previous study of ours, we have shown that zinterol, another  $\beta_2$ -adrenoceptor agonist, also stimulates frog  $I_{Ca}$  in a dose-dependent manner (Skeberdis *et al.*, 1996). While salbutamol and zinterol (Skeberdis *et al.*, 1996) increased  $I_{Ca}$  with a similar efficacy to isoprenaline, the efficacy of dobutamine was only half that of isoprenaline.  $EC_{50}$  values were calculated from the dose-response curves for the stimulating effects of the agonists on  $I_{Ca}$  which allowed us to determine the potency rank order for these agonists: zinterol (2.2 nM, Skeberdis *et al.*, 1996) > isoprenaline (20 nM) > salbutamol (290 nM) > dobutamine (2.4  $\mu$ M) > > xamoterol. Whatever the agonist used to stimulate  $I_{Ca}$ , their effect was antagonized by ICI 118551 ( $\beta_2$ -antagonist) and metoprolol ( $\beta_1$ -antagonist), as well as by xamoterol. Competition curve analysis by use of the Schild equation yielded a Schild coefficient of 1 (0.9–1.2) in all experimental conditions. This suggests that all the  $\beta$ -adrenoceptor agonists and antagonists tested competed on a single population of receptors. Equilibrium dissociation constants ( $K_B$ ) for the receptor-antagonist complex were calculated from the Schild equation in each experimental condition. This allowed us to determine a rank order of potency for the different antagonists: ICI 118551 (2–4 nM) > xamoterol (60 nM) > metoprolol (200–600 nM). We conclude that a single population of receptors is involved in the  $\beta$ -adrenoceptor regulation of  $I_{Ca}$  in frog ventricular myocytes. The pharmacological profiles obtained indicate that this population of receptors fits the criteria set for the  $\beta_2$ -adrenoceptor subtype in mammalian tissue.

Although initial competitive binding studies concluded that  $\beta_2$ -adrenoceptors are not present in purified ventricular myocytes from mammalian hearts (Lau *et al.*, 1980; Buxton & Brunton, 1985; Freissmuth *et al.*, 1986), more recent studies have clearly established the presence of these receptors in ventricular myocytes from several mammals, such as rats (Kuznetsov *et al.*, 1995; Cerbai *et al.*, 1995), dogs (Murphree & Saffitz, 1988), baboons (Cui *et al.*, 1996) and man (del Monte *et al.*, 1993). However, the  $\beta_1/\beta_2$  ratio may vary somewhat from one study to the other in a given animal species (e.g. 80/20 to 92/8 in rat myocytes: Cerbai *et al.*, 1995; Kuznetsov *et al.*, 1995; Cui *et al.*, 1996) and from one species to the other (e.g. 85/15 in dog: Murphree & Saffitz, 1988; 59/41 in baboon: Cui *et al.*, 1996). The  $\beta_1/\beta_2$  ratio may also vary depending on the pathophysiological state (Brodde, 1993; Ihl-Vahl *et al.*, 1996), the age (White *et al.*, 1994; Cerbai *et al.*, 1995) or the developmental stage (Kuznetsov *et al.*, 1995; for reviews, see Stiles *et al.*, 1984; Brodde, 1991; 1993; Hieble & Ruffolo, 1991 and references therein). Finally, the proportion of  $\beta_2$ -adrenoceptors was shown to be somewhat larger in atrial compared to ventricular tissues (Carlsson *et al.*, 1977; Hedberg *et al.*, 1980; Molenaar & Summers, 1987), and more so in human where  $\beta_2$ -adrenoceptors may account for 35–50% of the total number of  $\beta$ -receptors (Robberecht *et al.*, 1983; Brodde, 1991; Hieble & Ruffolo, 1991). The latter finding may explain why  $\beta_2$ -adrenoceptor agonists exert preferentially positive chronotropic rather than inotropic effects in man (Brodde, 1991).

Unlike in mammals, the  $\beta$ -adrenoceptors in the frog heart are composed of a majority of  $\beta_2$ -subtype. Radioligand bind-

ing experiments and competition curve analysis in frog myocardial membrane preparations have shown that the proportion of  $\beta_2$ -receptors may vary from 50% to 100% of the total population of  $\beta$ -receptors depending on the specific antagonist used to displace the radiolabelled ligand and the individual cell preparation (Hancock *et al.*, 1979; Port *et al.*, 1992). Measurements of force and rate of spontaneous contractions in the isolated heart (Lands *et al.*, 1969) or in isolated auricles (Stene-Larsen & Helle, 1978) of the frog have shown that the inotropic and chronotropic responses to various sympathomimetic amines are essentially mediated by  $\beta_2$ -adrenoceptors. This suggests that, although present in the sarcolemmal membrane,  $\beta_1$ -adrenoceptors may not be functionally coupled to the effectors involved in the contractile and electrical activities of the frog heart. Since the L-type  $Ca^{2+}$  channel current ( $I_{Ca}$ ) is one of the main actors in the excitation-contraction coupling of the frog heart, it was of interest to examine how this current is regulated by the two populations of  $\beta$ -adrenoceptors receptors.

Selective agonists of  $\beta_2$ -adrenoceptors were shown earlier to increase  $I_{Ca}$  in mammalian cardiac myocytes, such as guinea-pig atrial myocytes (Iijima & Taira, 1989), rat (Xiao & Lakatta, 1993; Cerbai *et al.*, 1995), dog (Altschuld *et al.*, 1995) and guinea-pig ventricular myocytes (Wang & Pelzer, 1995; but see Iijima & Taira, 1989). The maximal stimulating effect of these agonists on  $I_{Ca}$  varied from 30% in guinea-pig (Wang & Pelzer, 1995) to 100% in rat ventricular myocytes (Xiao & Lakatta, 1993) of the effect of isoprenaline. In frog cardiomyocytes, we found that selective activation of  $\beta_2$ -adrenoceptors with salbutamol (this study) or with zinterol (Skeberdis *et al.*, 1996) accounted for 100% of the isoprenaline response in frog ventricular myocytes. By comparison, the maximal stimulant effect of the  $\beta_1$ -agonist dobutamine on  $I_{Ca}$  was only about half that of isoprenaline, while xamoterol had no stimulant effect at all. Thus, the agonists acting more selectively on the  $\beta_2$ -adrenoceptors (zinterol, salbutamol) had a higher potency and efficacy in stimulating frog  $I_{Ca}$  than the agonists acting on the  $\beta_1$ -receptors (dobutamine, xamoterol). Moreover, the stimulating effect of dobutamine on  $I_{Ca}$  was probably mediated by activation of  $\beta_2$ -, and not  $\beta_1$ -, receptors. Indeed, dobutamine increased  $I_{Ca}$  with an  $EC_{50}$  of 2.4  $\mu$ M, which is two orders of magnitude higher than the concentration at which it binds selectively to mammalian  $\beta_1$ -receptors (Brodde, 1991). Moreover, the stimulating effect of dobutamine on  $I_{Ca}$  was strongly antagonized by ICI 118551 ( $K_B = 2.8$  nM) while it was only weakly antagonized by metoprolol ( $K_B = 609$  nM). While at a concentration of 2.8 nM ICI 118551 remains a highly selective antagonist of  $\beta_2$ -receptors (Bylund *et al.*, 1994), metoprolol is not selective for  $\beta_1$ -receptors anymore when its concentration approaches the micromolar range (Bylund *et al.*, 1994). Since ICI 118551 and metoprolol antagonized the stimulant effects of isoprenaline, dobutamine and salbutamol on  $I_{Ca}$  with the same  $K_B$  values (2–4 nM for ICI 118551, 200–600 nM for metoprolol) and the same Schild coefficient (equal to 1), it is likely that these agonists and antagonists produced their effects by binding exclusively to  $\beta_2$ -adrenoceptors. However, the frog  $\beta_2$ -receptor may differ somewhat from its mammalian counterpart since salbutamol increased  $I_{Ca}$  with an  $EC_{50}$  of 290 nM, which was about 10 fold higher than the concentration required to activate  $\beta_2$ -receptors in mammalian preparations (Bylund *et al.*, 1994). On the contrary, the frog cardiac  $\beta_2$ -receptor appears to be about 50 times more sensitive to zinterol than the mammalian cardiac  $\beta_2$ -receptor ( $EC_{50} = 2.2$  nM in frog myocytes, Skeberdis *et al.*, 1996;  $EC_{50} = 1$   $\mu$ M in rat myocytes, Xiao & Lakatta, 1993). Another peculiarity of the frog cardiac  $\beta_2$ -receptor is its relatively high sensitivity to xamoterol. While xamoterol alone had no effect on  $I_{Ca}$ , this partial  $\beta_1$ -agonist antagonized the stimulant effect of isoprenaline, dobutamine and salbutamol with a similar  $K_B$  value ( $\approx 60$  nM) independently of which agonist was used to stimulate  $I_{Ca}$ . The Schild coefficient was equal to 1 in all cases, demonstrating that xamoterol competed with the agonist on a single population of

receptors. Thus, xamoterol is an antagonist of frog  $\beta_2$ -receptors and binds to these receptors with an affinity which is comparable to that at which it binds to mammalian  $\beta_1$ -receptors (Brodde, 1991; Bylund *et al.*, 1994).

The major finding of our study is that the  $\beta$ -adrenoceptor regulation of  $I_{Ca}$  in frog cardiac myocytes is exclusively mediated by  $\beta_2$ -adrenoceptors. This observation is consistent with earlier functional data obtained on whole heart (Lands *et al.*, 1969) or multicellular cardiac preparations of the frog (Stene-Larsen & Helle, 1978). This finding is also consistent with the fact that the sympathetic nerves carry adrenaline in the frog (Loewi, 1936) and the  $\beta_2$ -receptor is, by definition, an 'adrenaline receptor' (Stene-Larsen & Helle, 1978). However, there is evidence for the presence of  $\beta_1$ -receptors in frog cardiac myocytes (Hancock *et al.*, 1979; Port *et al.*, 1992), and their relative proportion is comparable to that of  $\beta_2$ -receptors in mammalian cardiac myocytes (Hieble & Ruffolo, 1991). Interestingly,  $\beta_2$ -receptors have been shown to be more tightly coupled to the adenylyl cyclase than  $\beta_1$ -receptors (Waelbroeck *et al.*, 1983; Bristow *et al.*, 1989; Green *et al.*, 1992; Levy *et al.*, 1993). This may explain why  $\beta_2$ -adrenoceptors, although present in a minority in mammalian cardiac myocytes, are effi-

ciently coupled to  $I_{Ca}$  and contraction in these preparations (Xiao & Lakatta, 1993; Xiao *et al.*, 1994; 1995; Altschuld *et al.*, 1995; Kuznetsov *et al.*, 1995; Skeberdis *et al.*, 1996). In frog myocytes where they are present in a majority, the coupling of  $\beta_2$ -receptors to adenylyl cyclase may overwhelm that of  $\beta_1$ -receptors and nullify their contribution to the stimulation of  $I_{Ca}$ . Alternatively,  $\beta_2$ -receptors may lead to an elevation of adenosine 3':5'-cyclic monophosphate (cyclic AMP) in a compartment more efficiently coupled to L-type  $Ca^{2+}$  channels than  $\beta_1$ -receptors (Jurevičius & Fischmeister, 1996; Skeberdis *et al.*, 1996). Further experiments are needed to examine these hypotheses and to determine the function of  $\beta_1$ -receptors in the frog heart.

We thank Patrick Lechêne for skilful technical assistance, Florence Lefebvre and Isabelle Paic for preparation of the cells, and Dr Rémy Hanf for his contribution at an early stage of this study. This work was supported by a grant from the Foundation pour la Recherche Médicale. V.A.S. was supported by a fellowship from INSERM (Poste Vert).

## References

- ALTSCHULD, R.A., STARLING, R.C., HAMLIN, R.L., BILLMAN, G.E., HENSLEY, J., CASTILLO, L., FERTEL, R.H., HOHL, C.M., ROBITAILLE, P.M.L., JONES, L.R., XIAO, R.P. & LAKATTA, E.G. (1995). Response of failing canine and human heart cells to  $\beta_2$ -adrenergic stimulation. *Circulation*, **92**, 1612–1618.
- ARGIBAY, J.A., FISCHMEISTER, R. & HARTZELL, H.C. (1988). Inactivation, reactivation and pacing dependence of calcium current in frog cardiocytes: correlation with current density. *J. Physiol.*, **401**, 201–226.
- BILSKI, A.J., HALLIDAY, S.E., FITZGERALD, J.D. & WADE, J.L. (1983). The pharmacology of a  $\beta_2$ -selective adrenoceptor antagonist (ICI 118,551). *J. Cardiovasc. Pharmacol.*, **5**, 430–437.
- BOREA, P.A., AMERINI, S., MASINI, I., CERBAI, E., LEDDA, F., MANTELLI, L., VARANI, K. & MUGELLI, A. (1992).  $\beta_1$ -adrenoceptors and  $\beta_2$ -adrenoceptors in sheep cardiac ventricular muscle. *J. Mol. Cell. Cardiol.*, **24**, 753–763.
- BRISTOW, M.R., HERSHBERGER, R.E., PORT, J.D., MINOBE, W. & RASMUSSEN, R. (1989).  $\beta_1$ -adrenergic and  $\beta_2$ -adrenergic receptor-mediated adenylyl cyclase stimulation in nonfailing and failing human ventricular myocardium. *Mol. Pharmacol.*, **35**, 295–303.
- BRODDE, O.E. (1991).  $\beta_1$ -adrenoceptors and  $\beta_2$ -adrenoceptors in the human heart—properties, function, and alterations in chronic heart failure. *Pharmacol. Rev.*, **43**, 203–242.
- BRODDE, O.E. (1993). Beta-adrenoceptors in cardiac disease. *Pharmacol. Ther.*, **60**, 405–430.
- BUXTON, I.L.O. & BRUNTON, L.L. (1985). Direct analysis of  $\beta$ -adrenergic receptor subtypes on intact adult ventricular myocytes of the rat. *Circ. Res.*, **56**, 126–132.
- BYLUND, D.B., EIKENBERG, D.C., HIEBLE, J.P., LANGER, S.Z., LEFKOWITZ, R.J., MINNEMAN, K.P., MOLINOFF, P.B., RUFFOLO, R.R. & TRENDELENBURG, U. (1994). International union of pharmacology nomenclature of adrenoceptors. *Pharmacol. Rev.*, **46**, 121–136.
- CARLSSON, E., DAHLÖF, C.G., HEDBERG, A., PERSSON, H. & TANGSTRAND, B. (1977). Differentiation of cardiac chronotropic and inotropic effects of  $\beta$ -adrenoceptor agonists. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, **300**, 101–105.
- CERBAI, E., GUERRA, L., VARANI, K., BARBIERI, M., BOREA, P.A. & MUGELLI, A. (1995).  $\beta$ -Adrenoceptor subtypes in young and old rat ventricular myocytes: A combined patch-clamp and binding study. *Br. J. Pharmacol.*, **116**, 1835–1842.
- CERBAI, E., MASINI, I. & MUGELLI, A. (1990). Electrophysiological characterisation of cardiac  $\beta_2$ -adrenoceptors in sheep Purkinje fibers. *J. Mol. Cell. Cardiol.*, **22**, 859–870.
- CUI, Y.N., SHEN, Y.T., KALTHOF, B., IWASE, M., SATO, N., UECHI, M., VATNER, S.F. & VATNER, D.E. (1996). Identification and functional role of  $\beta$ -adrenergic receptor subtypes in primate and rodent: In vivo versus isolated myocytes. *J. Mol. Cell. Cardiol.*, **28**, 1307–1317.
- DEL MONTE, F.D., KAUMANN, J.A., POOLE-WILSON, P.A., WYNNE, D.G., PEPPER, J. & HARDING, S.E. (1993). Coexistence of functioning  $\beta_1$ - and  $\beta_2$ -adrenoceptors in single myocytes from human ventricle. *Circulation*, **88**, 854–863.
- FISCHMEISTER, R. & HARTZELL, H.C. (1986). Mechanisms of action of acetylcholine on calcium current in single cells from frog ventricle. *J. Physiol.*, **376**, 183–202.
- FREISSMUTH, M., HAUSLEITHNER, V., NEES, S., BOCK, M. & SCHUTZ, W. (1986). Cardiac ventricular  $\beta_2$ -adrenoceptors in guinea-pigs and rats are localised on the coronary endothelium. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, **334**, 56–62.
- GREEN, S.A., HOLT, B.D. & LIGGETT, S.B. (1992).  $\beta_1$ -adrenergic and  $\beta_2$ -adrenergic receptors display subtype-selective coupling to Gs. *Mol. Pharmacol.*, **41**, 889–893.
- HANCOCK, A.A., DELEAN, A.L. & LEFKOWITZ, R.J. (1979). Quantitative resolution of beta-adrenergic subtypes by selective ligand binding: application of a computerized model fitting technique. *Mol. Pharmacol.*, **16**, 1–9.
- HARTZELL, H.C., MÈRY, P.F., FISCHMEISTER, R. & SZABO, G. (1991). Sympathetic regulation of cardiac calcium current is due exclusively to cAMP-dependent phosphorylation. *Nature*, **351**, 573–576.
- HEDBERG, A., MINNEMAN, K.P. & MOLINOFF, P.B. (1980). Differential distribution of beta-1 and beta-2 adrenergic receptors in cat and guinea-pig heart. *J. Pharmacol. Exp. Ther.*, **212**, 503–508.
- HIEBLE, J.P. & RUFFOLO, R.R. (1991). Subclassification of  $\beta$ -adrenoceptors.  *$\beta$ -Adrenoceptors: Mol. Biol. Biochem. Pharmacol.*, **7**, 1–25.
- IHL-VAHL, R., ESCHENHAGEN, T., KÜBLER, W., MARQUETANT, R., NOSE, M., SCHMITZ, W., SCHOLZ, H. & STRASSER, R.H. (1996). Differential regulation of mRNA specific for  $\beta_1$ - and  $\beta_2$ -adrenergic receptors in human failing hearts. Evaluation of the absolute cardiac mRNA levels by two independent methods. *J. Mol. Cell. Cardiol.*, **28**, 1–10.
- IJIMA, T. & TAIRA, N. (1989).  $\beta_2$ -Adrenoceptor-mediated increase in the slow inward calcium current in atrial cells. *Eur. J. Pharmacol.*, **163**, 357–360.
- JUREVIČIUS, J. & FISCHMEISTER, R. (1996). Cyclic AMP compartmentation is responsible for a local activation of cardiac  $Ca^{2+}$  channels by  $\beta$ -adrenergic agonists. *Proc. Natl. Acad. Sci. U.S.A.*, **93**, 295–299.
- KENAKIN, T. (1993). *Pharmacologic Analysis of Drug-Receptor Interaction* (second edition). New York: Raven Press.
- KUZNETSOV, V., PAK, E., ROBINSON, R.B. & STEINBERG, S.F. (1995).  $\beta_2$ -Adrenergic receptor actions in neonatal and adult rat ventricular myocytes. *Circ. Res.*, **76**, 40–52.
- LANDS, A.M., LUDUENA, F.P. & BUZZO, H.J. (1969). Adrenotropic  $\beta$ -receptors in the frog and chicken. *Life Sci.*, **8**, 373–382.

- LAU, Y.H., ROBINSON, R.B., ROSEN, M.R. & BILEZIKIAN, J.P. (1980). Sub-classification of  $\beta$ -adrenergic receptors in cultured rat cardiac myoblasts and fibroblasts. *Circ. Res.*, **47**, 41–48.
- LEMOINE, H. & KAUMANN, A.J. (1991). Regional differences of  $\beta_1$ -adrenoceptor-mediated and  $\beta_2$ -adrenoceptor-mediated functions in feline heart—A  $\beta_2$ -adrenoceptor-mediated positive inotropic effect possibly unrelated to cyclic AMP. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, **344**, 56–69.
- LEVY, F.O., ZHU, X., KAUMANN, A.J. & BIRNBAUMER, L. (1993). Efficacy of beta(1)-adrenergic receptors is lower than that of beta(2)-adrenergic receptors. *Proc. Natl. Acad. Sci. U.S.A.*, **90**, 10798–10802.
- LOEWI, O. (1936). Quantitative und qualitative Untersuchungen über den Sympaticusstoff. *Pflügers Arch.*, **237**, 504–514.
- MOLENAAR, P. & SUMMERS, R.J. (1987). Characterisation of Beta-1 and Beta-2 adrenoceptors in guinea-pig atrium. Functional and receptor binding studies. *J. Pharmacol. Exp. Ther.*, **241**, 1041–1047.
- MURPHREE, S.S. & SAFFITZ, J.E. (1988). Delineation of the distribution of  $\beta$ -adrenergic receptor subtypes in canine myocardium. *Circ. Res.*, **63**, 117–125.
- PORT, J.D., DEBELLIS, C.C., KLEIN, J., PEETERS, G.A., BARRY, W.H. & BRISTOW, M.R. (1992). Pharmacological characterization of chick and frog  $\beta$ -adrenergic receptors in primary cultures of myocardial cells. *J. Pharmacol. Exp. Ther.*, **262**, 217–224.
- ROBBERECHT, P., DELHAYE, M., TATON, G., DE NEEF, P., WAELBROECK, M., DE SMET, J.M., LECLERC, J.L., CHATELAIN, P. & CHRISTOPHE, J. (1983). The human heart  $\beta$ -adrenergic receptors. 1. Heterogeneity of the binding sites: presence of 50%  $\beta_1$ - and 50%  $\beta_2$ -adrenergic receptors. *Mol. Pharmacol.*, **24**, 169–173.
- SKEBERDIS, V.A., JUREVIČIUS, J. & FISCHMEISTER, R., (1996).  $\beta_2$ -Adrenergic activation of cardiac Ca current is due to cAMP-dependent phosphorylation in frog ventricle. *J. Mol. Cell. Cardiol.*, **28**, A245 (Abstract).
- SKEBERDIS, V.A., JUREVIČIUS, J. & FISCHMEISTER, R. (1997). Pharmacological characterization of the receptors involved in the  $\beta$ -adrenergic stimulation of the L-type Ca current in frog ventricular myocytes. *Biophys. J.*, **72**, A34 (Abstract).

- STENE-LARSEN, G. & HELLE, K.B. (1978). Cardiac  $\beta_2$ -adrenoceptor in the frog. *Comp. Biochem. Physiol.*, **60C**, 165–173.
- STILES, G.L., CARON, M.C. & LEFKOWITZ, R.J. (1984).  $\beta$ -Adrenergic receptors: biochemical mechanisms of physiological regulation. *Physiol. Rev.*, **64**, 661–743.
- WAELEBROECK, M., TATON, G., DELHAYE, M., CHATELAIN, P., CAMUS, J.C., POCHE, R., LECLERC, J.L., DE SMET, J.M., ROBBERECHT, P. & CHRISTOPHE, J. (1983). The human heart  $\beta$ -adrenergic receptors. 2. Coupling of  $\beta_2$ -adrenergic receptors with the adenylate system. *Mol. Pharmacol.*, **24**, 174–182.
- WANG, J. & PELZER, D.J. (1995). Contribution of  $\beta_1$  and  $\beta_2$  adrenoceptors to the sympathetic stimulation of L-type  $\text{Ca}^{2+}$  current in isolated guinea-pig ventricular cardiomyocytes. *J. Physiol.*, **489**, 50P–51P.
- WHITE, M., RODEN, R., MINOBE, W., KHAN, M.F., LARRABEE, P., WOLLMERING, M., PORT, J.D., ANDERSON, F., CAMPBELL, D., FELDMAN, A.M. & BRISTOW, M.R. (1994). Age-related changes in  $\beta$ -adrenergic neuroeffector systems in the human heart. *Circulation*, **90**, 1225–1238.
- XIAO, R.P. & LAKATTA, E.G. (1993).  $\beta_1$ -adrenoceptor stimulation and  $\beta_2$ -adrenoceptor stimulation differ in their effects on contraction, cytosolic  $\text{Ca}^{2+}$ , and  $\text{Ca}^{2+}$  current in single rat ventricular cells. *Circ. Res.*, **73**, 286–300.
- XIAO, R.P., HOHL, C., ALTSCHULD, R., JONES, L., LIVINGSTON, B., ZIMAN, B., TANTINI, B. & LAKATTA, E.G. (1994). Beta(2)-adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in  $\text{Ca}^{2+}$  dynamics, contractility, or phospholamban phosphorylation. *J. Biol. Chem.*, **269**, 19151–19156.
- XIAO, R.P., JI, X.W., & LAKATTA, E.G. (1995). Functional coupling of the  $\beta(2)$ -adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. *Mol. Pharmacol.*, **47**, 322–329.